ADVERTISEMENT
Poster
1587197
Adjunctive Cariprazine in Patients With Major Depressive Disorder: A Post Hoc Analysis of Efficacy and Safety by Background Antidepressant Therapy
Psych Congress 2023
This work was sponsored by AbbVie
Background: Post hoc analyses evaluated cariprazine by antidepressant treatment (ADT) response, number of current episode ADTs, and class of ongoing ADT using data from a phase 3 trial of cariprazine 1.5 or 3 mg/d+ADT (NCT03738215) in patients with major depressive disorder and inadequate response to monotherapy ADT.
Methods: Patient data were stratified by level of partial response to ongoing ADT (≥25% to
Sign Up
Psych Congress Network Newsletter
